Baidu
map

Pediatrics:2014-2019年美国常见儿科手术后常规阿片类药物的使用趋势

2022-05-21 liangying MedSci原创

自2017年起,填写阿片类药物处方的儿童比例和分发的阿片类药物数量均大幅下降,这种下降的开始因年龄组和手术的不同而不同。

阿片类药物通常用于与轻中度疼痛相关的普通儿科手术。然而,有证据表明,无论是使用有限的阿片类药物还是不使用阿片类药物,康复情况都是相似的。儿童中,术后过度阿片类药物暴露与不良结果相关,如呼吸抑制等。研究评估了术后阿片类药物处方随时间的变化趋势,以确定处方是否减少。

研究者们使用了一个私人保险数据库研究年龄小于18岁患者的阿片类药物使用情况,他们在2014年至2019年期间至少接受了8例外科手术中的1例。主要观察指标为术后7天内填写阿片类药物处方的可能性,次要观察指标为阿片类药物处方总量。使用Joinpoint回归分析来识别趋势中的时间变化。

最后,本研究队列共纳入124249名opioid-naïve儿童。青少年中填写阿片类药物处方的比例从78.2%下降到48.0%,学龄儿童从53.9%下降到25.5%,学龄前儿童从30.4%下降到11.5%。在青少年中,吗啡的平均剂量从228.9毫克下降到110.8毫克,在学龄儿童中从121.3毫克下降到65.9毫克,在学龄前儿童中从75.3毫克下降到33.2毫克。使用Joinpoint回归分析发现从2017年底开始,阿片类药物的快速脱瘾首先发生在青少年,然后是学龄和学龄前儿童。

2014年至2019年按年龄组划分的Joinpoint回归模型。专家组包括(A)术后接受阿片类药物处方的可能性,以及(B)术后7天内首次服用阿片类药物处方时MME中的阿片类药物总量(具体针对3个年龄组)

简单来说,通过2014年至2019年期间的研究结果发现,自2017年起,填写阿片类药物处方的儿童比例和分发的阿片类药物数量均大幅下降。这种下降的开始因年龄组和手术的不同而不同。

参考文献:Sutherland TN, Wunsch H, Newcomb C, et al. Trends in Routine Opioid Dispensing After Common Pediatric Surgeries in the United States: 2014–2019. Pediatrics. 2022;149(5):e2021054729

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640149, encodeId=bb7e1640149d3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 21 05:35:18 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729561, encodeId=995d1e29561c3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jan 08 22:35:18 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958580, encodeId=cd8919585801b, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 28 00:35:18 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253144, encodeId=43de1253144b6, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309202, encodeId=32e1130920288, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640149, encodeId=bb7e1640149d3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 21 05:35:18 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729561, encodeId=995d1e29561c3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jan 08 22:35:18 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958580, encodeId=cd8919585801b, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 28 00:35:18 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253144, encodeId=43de1253144b6, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309202, encodeId=32e1130920288, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2023-01-08 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640149, encodeId=bb7e1640149d3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 21 05:35:18 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729561, encodeId=995d1e29561c3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jan 08 22:35:18 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958580, encodeId=cd8919585801b, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 28 00:35:18 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253144, encodeId=43de1253144b6, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309202, encodeId=32e1130920288, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2023-02-28 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1640149, encodeId=bb7e1640149d3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 21 05:35:18 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729561, encodeId=995d1e29561c3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jan 08 22:35:18 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958580, encodeId=cd8919585801b, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 28 00:35:18 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253144, encodeId=43de1253144b6, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309202, encodeId=32e1130920288, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1640149, encodeId=bb7e1640149d3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Sep 21 05:35:18 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729561, encodeId=995d1e29561c3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jan 08 22:35:18 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958580, encodeId=cd8919585801b, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Feb 28 00:35:18 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253144, encodeId=43de1253144b6, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309202, encodeId=32e1130920288, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu May 19 00:35:18 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-05-19 lhlxtx

相关资讯

Med J Aust:阿片类药物治疗对骨关节炎患者的镇痛效果可能并不理想

骨关节炎影响着全世界5亿多人,它是导致残疾的主要原因之一。对阿片类药物治疗骨关节炎疼痛有效性的安慰剂对照试验的系统回顾,范围有限。

不使用阿片类药物的麻醉,你觉得靠谱吗?

无阿片的多模式麻醉,包括右美托咪定和艾司氯胺酮对接受妇科腹腔镜检查的患者,是可行的,且易于管理。然而,在手术第一天后的恶心呕吐、疼痛评分和吗啡用量方面,它没有显示出明显的优势。

Lancet Psychiatry:药物成瘾性情大变?阿片受体激动剂治疗期间明显降低自残风险!

阿片受体激动剂治疗的稳定期与自残风险的降低有关

Int J Dermatol:皮肤科医生的全身性阿片类药物真的用对了吗?

皮肤科医生治疗许多以疼痛为主要特征的皮肤病,这项系统的综述旨在综合皮肤科医生使用阿片类药物的现有证据,可能有助于为皮肤科关于阿片类药物处方的建议或指南提供信息。

Age & Ageing:老年人总是喊疼?阿片类药物对老年人认知功能的影响

老年人中,约有80%的人报告有持续的疼痛。

Baidu
map
Baidu
map
Baidu
map